Spikevax® Generated $6.7 Billion in Vaccine Sales

Moderna Inc. today reported $2.8 billion in Spikevax® vaccine sales in the fourth quarter of 2023. The majority of Spikevax sales ($2 billion) were in international sales.

For all of 2023, Spikevax generated $6.7 billion in vaccine sales.

Moderna confirmed in a press release on February 24, 2024, that it achieved 48% cumulative market share in the U.S. retail segment during the fall 2023 COVID season, up from 37% in 2022.

The Company reaffirmed its 2024 product sales outlook as it entered the second year of the U.S. commercial endemic COVID market.

Moderna is also prioritizing key international markets for greater commercial focus and is participating in the EU Health Emergency and Response Authority's tendering procedure for up to 36 million doses of mRNA COVID-19 vaccines per year for up to four years.

As of February 2024, Spikevax is one of 13 COVID-19 vaccines Listed by the World Health Organization.

"2023 was a year of transition for Moderna as we adapted to the endemic market. At the same time, our development team made significant pipeline advancements across infectious diseases, oncology, and rare diseases, while our commercial team increased our COVID-19 market share in the U.S.," said Stéphane Bancel, Chief Executive Officer of Moderna, in a press release.